IRVINE, Calif., Aug. 17, 2011 /PRNewswire/ -- Endologix, Inc.
(Nasdaq: ELGX), developer and marketer of minimally invasive
treatments for aortic disorders, announced today that Judge
Tanya Walton Pratt of the United
States District Court for the Southern District of Indiana in Indianapolis has issued a Markman ruling in
the ongoing patent infringement lawsuit filed against the Company
by Cook Medical.
In a Markman ruling, the court determines the meaning of
disputed patent claim terms at issue in patent litigation.
After a briefing and oral argument on April 15, 2011 as to the meaning of a number of
terms of the claims of the two patents that Cook is asserting in
the lawsuit, Judge Pratt adopted many of Endologix's proposed
constructions for several terms of claims of both asserted patents,
including constructions that the Company considers to be important
for the outcome of the case.
The trial date for the patent infringement lawsuit has not yet
been set but is expected to be set for fall 2012.
John McDermott, President and
Chief Executive Officer of Endologix, commented, "We are pleased
with the results of the Markman hearing, remain confident in our
position going forward and intend to continue to pursue our
numerous defenses."
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix's Web site at
www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements relating to the
continuing litigation with Cook Medical. The
achievement of the plans and objectives in such statements involves
risks and uncertainties including, but not limited to, risks and
uncertainties related to the costs and outcome of intellectual
property litigation, many of which are difficult or impossible to
predict accurately and many of which are beyond the control of
Endologix. The Company undertakes no obligation to update its
forward looking statements. Please refer to the Company's Annual
Report on Form 10-K for the year ended December 31, 2010, and the Company's other
filings with the Securities and Exchange Commission, for more
detailed information regarding these risks and other factors that
may cause actual results to differ materially from those expressed
or implied.
|
|
|
|
|
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646)
536-7020
|
|
www.endologix.com
|
|
|
|
|
|
|
SOURCE Endologix, Inc.